**TTK Healthcare**
LIMITED

**TTKH:SECL:GJ:188:18** **August 09, 2018**

**National Stock Exchange of India Limited (NSE)**
**Exchange Plaza**
**Bandra Kurla Complex**
**Bandra East**
**Mumbai 400 051**

**Scrip Code : TTKHLTCARE**

**Dear Sirs,**

**Re : Limited Review – Auditor's Report**

We are forwarding herewith a copy of Limited Review – Auditor's Report, in respect of the Unaudited Financial Results of the Company for the First Quarter ended 30th June, 2018, approved by the Board of Directors of the Company at their meeting held today.

Kindly take the above document on record.

Thanking you

Yours faithfully
**For TTK Healthcare Limited**

**(S KALYANARAMAN)**
*Director & Wholetime Secretary*

**Encl. : a/a**

Regd. Office : No. 6, Cathedral Road, Chennai - 600 086, INDIA
Phone : 91-44-28116106 - 08, Fax : 91-44-28116387
Email : info@ttkhealthcare.com Website : www.ttkhealthcare.com
CIN : L24231TN1958PLC003647

**PKF SRIDHAR & SANTHANAM LLP**

**Chartered Accountants**

**Independent Auditor's Review Report on review of Interim financial results**

**To the Board of Directors of TTK Healthcare Limited**

We have reviewed the Unaudited financial results of TTK Healthcare Limited ("the Company") for the quarter ended 30th June 2018 which are included in the accompanying 'Financial Results for the quarter ended 30th June 2018 together with the notes thereon ("the Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016 which has been initialed by us for identification purposes.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 *'Review of Interim Financial Information performed by the Independent Auditor of the Entity'*, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Figures for the quarter ended 30th June 2017 include the figures of TTK Healthcare limited, (pre-merger), which have been reviewed by M/s Aiyar & Co, Chartered Accountants (Firm's Registration No.000063S) and M/s S.Viswanathan LLP, Chartered Accountants (Firm Registration No.004770S) and the management certified figures of TTK Protective Devices Limited, which Company got merged with TTK Healthcare Limited during the year 2017-18 pursuant to Court order received in December 2017.

The report of the predecessor auditor, on the comparative financial information of TTK Healthcare limited (pre-merger) for the quarter ended 30'th June 2017 expressed an unmodified conclusion.

Our conclusion is not modified in respect of the said matter.

For PKF Sridhar & Santhanam LLP
Chartered Accountants
Firm's Registration No. 003990S/S200018

S. Rajeshwari
Partner
Membership No. 024105
Place: Chennai
Date: 09-08-2018

PKF SRIDHAR & SANTHANAM LLP * CHENNAI * Firm Regn. No.: 003990S/S200018

# TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2018

[Prepared in compliance with the Indian Accounting Standards (Ind AS)]

(Rs. in lakhs)

| S. No. | Particulars | For the Quarter ended | | | For the Year ended |
|---|---|---|---|---|---|
| | | (30/06/2018) | (31/03/2018) | (30/06/2017) | (31/03/2018) |
| | | Unaudited | Audited | Unaudited | Audited |
| I. | Revenue from Operations | 17,313.10 | 14,510.70 | 12,996.53 | 57,754.65 |
| II. | Other Income | 183.35 | 231.12 | 173.83 | 757.47 |
| **III.** | **Total Income (I + II)** | **17,496.45** | **14,741.82** | **13,170.36** | **58,512.12** |
| IV. | Expenses | | | | |
| | (a) Cost of materials consumed | 2,289.14 | 2,545.76 | 1,803.33 | 8,713.56 |
| | (b) Purchase of Stock-in-trade | 4,643.67 | 3,621.06 | 4,193.79 | 15,437.58 |
| | (c) Changes in inventories of Finished Goods, Work-in-progress and Stock-in-trade | 125.76 | 243.71 | (557.27) | 8.20 |
| | (d) Employee benefits expense | 3,395.71 | 2,799.65 | 3,152.45 | 12,011.55 |
| | (e) Finance Costs | 104.93 | 96.10 | 115.08 | 472.93 |
| | (f) Depreciation and Amortization Expense | 363.82 | 362.89 | 394.15 | 1,524.22 |
| | (g) Other Expenses | 5,277.93 | 3,707.48 | 5,396.20 | 17,329.37 |
| | **Total Expenses (IV)** | **16,200.96** | **13,376.65** | **14,497.73** | **55,497.41** |
| **V.** | **Profit / (Loss) before Exceptional Items and Tax (III - IV)** | **1,295.49** | **1,365.17** | **(1,327.37)** | **3,014.71** |
| VI. | Exceptional Items | - | - | - | - |
| **VII.** | **Profit / (Loss) before Tax (V - VI)** | **1,295.49** | **1,365.17** | **(1,327.37)** | **3,014.71** |
| VIII. | Tax Expense: | | | | |
| | (1) Current Tax | 490.00 | 445.00 | - | 1,125.00 |
| | (2) Deferred Tax | 17.69 | 121.00 | - | 73.18 |
| **IX.** | **Profit / (Loss) for the period from Continuing Operations (VII-VIII)** | **787.80** | **799.17** | **(1,327.37)** | **1,816.53** |
| X. | Profit / (Loss) from Discontinued Operations | - | - | - | - |
| XI. | Tax Expense of Discontinued Operations | - | - | - | - |
| XII. | Profit / (Loss) from Discontinued Operations (after tax) (X -XI) | - | - | - | - |
| **XIII.** | **Profit / (Loss) for the period (IX + XII)** | **787.80** | **799.17** | **(1,327.37)** | **1,816.53** |
| XIV. | **Other Comprehensive Income:** | | | | |
| | (A) (i) Items that will not be reclassified subsequently to profit or loss | (58.48) | (164.79) | 108.51 | 104.65 |
| | (ii) Income tax relating to items that will not be reclassified to profit or loss | - | (21.22) | - | (21.22) |
| | (B) (i) Items that will be reclassified to profit or loss | - | - | - | - |
| | (ii) Income tax relating to items that will be reclassified to profit or loss | - | - | - | - |
| **XV.** | **Total Comprehensive Income for the period (XIII + XIV) [Comprising Profit / (Loss) and Other Comprehensive Income for the period]** | **729.32** | **613.16** | **(1,218.86)** | **1,899.96** |
| | Paid-up Equity Share Capital (Face Value Rs.10 per share) | **1,413.03** | **1,413.03** | **1,413.03** | **1,413.03** |
| | Reserve as per Balance Sheet of previous accounting year | - | - | - | **21,884.41** |
| **XVI.** | **Earnings per Equity Share (For Continuing Operations):** | | | | |
| | (1) Basic (in Rs.) | 5.58 | 5.66 | (9.39) | 12.86 |
| | (2) Diluted (in Rs.) | 5.58 | 5.66 | (9.39) | 12.86 |
| **XVII.** | **Earnings per Equity Share (For Discontinued Operation):** | | | | |
| | (1) Basic (in Rs.) | - | - | - | - |
| | (2) Diluted (in Rs.) | - | - | - | - |
| **XVIII.** | **Earnings per Equity Share (For Discontinued and Continuing Operation):** | | | | |
| | (1) Basic (in Rs.) | 5.58 | 5.66 | (9.39) | 12.86 |
| | (2) Diluted (in Rs.) | 5.58 | 5.66 | (9.39) | 12.86 |

PKF SRIDHAR & SANTHANAM LLP * CHENNAI * Firm Regn. No.: 003990S/S200018

**Notes:**

(1) The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 9th August, 2018 at Chennai.

(2) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(3) The previous year First Quarter Results (30th June, 2017) include the figures of Protective Devices Division which merged with the Company, pursuant to the Order dated 15th December, 2017 passed by the National Company Law Tribunal (NCLT), Division Bench, Chennai, the Appointed Date being 1st April, 2012.

(4) The previous year First Quarter (30th June, 2017) Paid-up Share Capital of Rs.1413.03 lakhs include Rs.636.43 lakhs subsequently allotted to the Shareholders of the erstwhile TTK Protective Devices Limited pursuant to the sanctioned Scheme.

(5) Ind AS 115 - Revenue from Contracts with Customers mandatory for reporting period beginning on or after 1st April, 2018 replaces the existing revenue recognition requirements. The application of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related items in the Financial Results.

(6) The figures for the quarter ended 31st March, 2018 are the balancing figures between audited figures in respect of the full financial year and published unaudited year to date figures upto the end of the Third Quarter of relevant financial year, which was subjected to Limited Review.

(7) The previous period's / year's figures have been regrouped and reclassfied, wherever necessary to conform to the current period's presentation.

(8) This Statement is also available on the website of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).

**For TTK HEALTHCARE LIMITED**

**Place:** Chennai
**Date:** August 09, 2018

**T T RAGHUNATHAN**
**EXECUTIVE VICE CHAIRMAN**



# TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

## SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER ENDED 30TH JUNE, 2018

(Rs. in lakhs)

| S. No. | Particulars | For the Quarter ended | | | For the Year ended |
|---|---|---|---|---|---|
| | | (30/06/2018) | (31/03/2018) | (30/06/2017) | (31/03/2018) |
| | | Unaudited | Audited | Unaudited | Audited |
| 1. | **Segment Revenue: (Sales and Other Operating Income)** | | | | |
| | (a) Pharmaceuticals | 5,553.63 | 4,670.90 | 3,520.43 | 19,233.47 |
| | (b) Consumer Products | 6,259.00 | 3,843.38 | 5,481.87 | 18,429.11 |
| | (c) Medical Devices | 1,133.80 | 935.98 | 746.42 | 3,265.18 |
| | (d) Protective Devices | 2,749.95 | 3,407.92 | 1,438.39 | 10,066.98 |
| | (e) Foods | 1,595.53 | 1,639.67 | 1,783.41 | 6,701.02 |
| | (f) Others | 21.19 | 12.85 | 26.01 | 58.89 |
| | **Total** | **17,313.10** | **14,510.70** | **12,996.53** | **57,754.65** |
| | **Less :** Inter Segment Revenue | - | - | - | - |
| | **Net Sales / Income from Operations** | **17,313.10** | **14,510.70** | **12,996.53** | **57,754.65** |
| 2. | **Segment Results: [Profit (+) / Loss (-) before tax and interest from each segment]** | | | | |
| | (a) Pharmaceuticals | 424.02 | 286.83 | (358.33) | 1,323.86 |
| | (b) Consumer Products | 1,130.00 | 796.78 | 360.19 | 2,871.16 |
| | (c) Medical Devices | 275.01 | 292.69 | 151.65 | 765.70 |
| | (d) Protective Devices | (5.17) | 466.95 | (923.44) | 206.94 |
| | (e) Foods | (177.13) | (203.80) | (196.05) | (728.67) |
| | (f) Others | 10.68 | 4.76 | 8.42 | 17.17 |
| | **Total** | **1,657.41** | **1,644.21** | **(957.56)** | **4,456.16** |
| | **Less : Finance Cost** | 104.93 | 96.10 | 115.08 | 472.93 |
| | **Less :** Unallocable Expenses (Net of Unallocable Income) | 256.99 | 182.94 | 254.73 | 968.52 |
| | **Total Profit (+) / Loss (-) before tax** | **1,295.49** | **1,365.17** | **(1,327.37)** | **3,014.71** |
| | | **As on 30/06/2018** | **As on 31/03/2018** | **As on 30/06/2017** | **As on 31/03/2018** |
| 3. | **Segment Assets** | | | | |
| | (a) Pharmaceuticals | 5,050.10 | 4,356.87 | 3,565.32 | 4,356.87 |
| | (b) Consumer Products | 3,498.91 | 2,603.78 | 3,081.82 | 2,603.78 |
| | (c) Medical Devices | 3,638.30 | 3,061.00 | 2,701.55 | 3,061.00 |
| | (d) Protective Devices | 8,961.40 | 11,190.03 | 10,553.70 | 11,190.03 |
| | (e) Foods | 9,739.10 | 9,815.26 | 10,167.93 | 9,815.26 |
| | (f) Others | 90.60 | 75.44 | 80.24 | 75.44 |
| | **Total** | **30,978.41** | **31,102.38** | **30,150.56** | **31,102.38** |
| | Unallocated | 13,491.78 | 12,166.78 | 11,541.63 | 12,166.78 |
| | **Total Assets** | **44,470.19** | **43,269.16** | **41,692.19** | **43,269.16** |
| 4. | **Segment Liabilities** | | | | |
| | (a) Pharmaceuticals | 4,573.01 | 3,829.48 | 3,901.15 | 3,829.48 |
| | (b) Consumer Products | 5,263.48 | 4,247.11 | 4,619.27 | 4,247.11 |
| | (c) Medical Devices | 958.71 | 769.33 | 899.31 | 769.33 |
| | (d) Protective Devices | 2,275.34 | 2,531.04 | 3,259.25 | 2,531.04 |
| | (e) Foods | 761.19 | 867.26 | 970.12 | 867.26 |
| | (f) Others | 140.38 | 136.15 | 135.57 | 136.15 |
| | **Total** | **13,972.11** | **12,380.37** | **13,784.67** | **12,380.37** |
| | Unallocated | 4,823.37 | 4,333.36 | 3,879.92 | 4,333.36 |
| | **Total Liabilities** | **18,795.48** | **16,713.73** | **17,664.59** | **16,713.73** |

PKF SRIDHAR & SANTHANAM LLP * CHENNAI *

**Notes:**

1. Segments have been identified in line with the Indian Accounting Standard on Operating Segments (Ind AS 108) considering the organisation structure and the differential risks and returns of these segments.
2. Details of products included in each of the Segments are as below :
   - ❖ Pharmaceuticals include products for both Human and Veterinary use.
   - ❖ Consumer Products comprise of marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Freshners, etc., (Own Brands).
   - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
   - ❖ Protective Devices comprise of manufacturing and marketing of Male Contraceptives and other allied products.
   - ❖ Foods comprise of manufacturing and marketing of Food Products.
   - ❖ "Others" include Printing and Publishing of Maps and Atlases.
3. The segment-wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
4. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

**For TTK HEALTHCARE LIMITED**

**Place:** Chennai
**Date:** August 09, 2018

**T T RAGHUNATHAN**
**EXECUTIVE VICE CHAIRMAN**



# TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

## EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2018

(Rs. in lakhs)

| Sl. No. | Particulars | For the Quarter ended | | | For the Year ended |
|---|---|---|---|---|---|
| | | (30/06/2018) | (31/03/2018) | (30/06/2017) | (31/03/2018) |
| | | Unaudited | Audited | Unaudited | Audited |
| 1. | Total income from Operations | 17,313.10 | 14,510.70 | 12,996.53 | 57,754.65 |
| 2. | Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items) | 1,295.49 | 1,365.17 | (1,327.37) | 3,014.71 |
| 3. | Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items) | 1,295.49 | 1,365.17 | (1,327.37) | 3,014.71 |
| 4. | Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items) | 787.80 | 799.17 | (1,327.37) | 1,816.53 |
| 5. | Total comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)] | 729.32 | 613.16 | (1,218.86) | 1,899.96 |
| 6. | Equity Share Capital (Face Value of Rs.10/- per share) | 1,413.03 | 1,413.03 | 1,413.03 | 1,413.03 |
| 7. | Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year | | | | 21,884.41 |
| 8. | Earnings per share (of Rs.10/- each) (for continuing and discontinued operations) | | | | |
| | (a) Basic (in Rs.) | 5.58 | 5.66 | (9.39) | 12.86 |
| | (b) Diluted (in Rs.) | 5.58 | 5.66 | (9.39) | 12.86 |

**Notes:**

(1) The above is an extract of the detailed Statement of Unaudited Financial Results for the First Quarter ended 30th June, 2018, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(2) The full financial results for the First Quarter ended 30th June, 2018 are available on the website of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).

(3) These financial results have been reviewed by the Audit Committee of the Company and approved by the Board of Directors at their Meeting held on 9th August, 2018.

(4) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(5) The previous year First Quarter Results (30th June, 2017) include the figures of Protective Devices Division which merged with the Company, pursuant to the Order dated 15th December, 2017 passed by the National Company Law Tribunal (NCLT), Division Bench, Chennai, the Appointed Date being 1st April, 2012.

(6) The previous year First Quarter (30th June, 2017) Paid-up Share Capital of Rs.1413.03 lakhs include Rs.636.43 lakhs subsequently allotted to the Shareholders of the erstwhile TTK Protective Devices Limited pursuant to the sanctioned Scheme.

(7) Ind AS 115 - Revenue from Contracts with Customers mandatory for reporting period beginning on or after 1st April, 2018 replaces the existing revenue recognition requirements. The application of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related items in the Financial Results.

(8) The previous period's / year's figures have been regrouped and reclassfied, wherever necessary to conform to the current period's presentation.

**For TTK HEALTHCARE LIMITED**

**Place: Chennai**
**Date: August 09, 2018**

**T T RAGHUNATHAN**
**EXECUTIVE VICE CHAIRMAN**